Price Band
₹120 - ₹128
Lot Size
1000
Issue Size
₹27.52 Cr
GMP
N/A
Subscription
74.39x
Analyzing...
IPO Schedule
1
Open
7 Nov 2025
2
Close
11 Nov 2025
3
Allotment
12 Nov 2025
4
Listing
14 Nov 2025
About Curis Lifesciences Ltd
Curis Lifesciences Ltd is an SME engaged in the marketing and distribution of pharmaceutical products. They operate primarily through third-party manufacturers, focusing on branded generics and specialty products.
Key Strengths
- High Return on Equity (ROE) of 55.25% indicates efficient utilization of shareholder funds.
- Relatively low Price-to-Earnings (P/E) ratio of 12.44 suggests a potentially undervalued offering compared to industry peers (though SME valuations differ).
- Established distribution network and relationships with key stakeholders.
- Focus on branded generics and specialty products allows for potentially higher margins compared to commodity generics.
- Experienced management team with a proven track record in the pharmaceutical industry.
Risk Factors
- •Reliance on third-party manufacturers exposes the company to supply chain disruptions and quality control issues.
- •Competition from larger, more established pharmaceutical companies with greater resources.
- •Dependence on regulatory approvals and changes in government policies related to pharmaceuticals.
Valuation Analysis
The IPO appears reasonably valued considering the company's ROE and P/E ratio, but investors should consider the risks associated with SME IPOs and the company's reliance on third-party manufacturers before investing.
IPO Details
ExchangeNSE
SegmentSME
ISININE1BZN01016
NSE SymbolCURIS
Face Value₹10
Lot Size1000
Issue Size₹27.52 Cr
Key Metrics
ROE55.25%
ROCE27.83%
P/E Ratio12.44
Industry P/E25
EPS10.29
PAT Margin12.43%
Debt/Equity0.96
Growth & Quality
Revenue Growth (YoY)41.2%
ProfitableYes ✓
Anchor Investors7
Subscription
Total3.07x
Imbalance Ratio1.3x
Documents
Registrar
LINK
Key Dates
Open Date7 Nov 2025
Close Date11 Nov 2025
Allotment12 Nov 2025
Listing14 Nov 2025